Floatz logo

cd19+cd22 car-t

Refractory Indolent Adult Non-Hodgkin Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.Cell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Refractory Indolent Adult Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Glofitamab
The Lymphoma Academic Research Organisation
Phase 2B
Cord Blood-Derived Expanded Allogeneic Natural Killer Cells
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

cd19+cd22 car-t is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
Childhood Acute Lymphoblastic LeukemiaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →